Welcome to our dedicated page for Rcm Tech SEC filings (Ticker: RCMT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
When you open RCM Technologies’ latest filings, you’re usually hunting for two things: how its Engineering and Specialty Health Care segments performed, and whether management is buying shares before new contracts drop. That information is scattered across the 300-page 10-K, multiple 10-Qs, and a steady stream of Form 4s. Our dedicated RCMT SEC filings page assembles every disclosure in one place and, with Stock Titan’s AI-powered summaries, turns dense tables into clear narratives.
Use the quick links to jump directly to an RCMT quarterly earnings report 10-Q filing, scan an RCMT insider trading Form 4 transactions feed, or review an RCMT proxy statement executive compensation section. Need a rapid read-through? The platform highlights segment revenue shifts, billable head-count trends, and client concentration risks—exactly what analysts ask when comparing project-based engineering revenue against cyclical staffing demand. Our AI also flags each RCMT 8-K material events explained note minutes after it hits EDGAR, so you never miss a new contract award or leadership change.
Whether you’re understanding RCMT SEC documents with AI for the first time or deep-diving into an RCMT annual report 10-K simplified, you’ll find:
- Live dashboard shows RCMT Form 4 insider transactions real-time
- Side-by-side RCMT earnings report filing analysis revealing margin trends by segment
- Editable notebooks that let you export AI-extracted KPIs straight to your model
Stop scrolling through PDFs: Stock Titan delivers every RCMT filing, update, and AI insight as soon as it’s published—so you can make informed decisions faster.
Tectonic Therapeutic, Inc. (Nasdaq: TECX) has filed a Form S-3 shelf registration that allows the company to issue up to $400 million of common stock, preferred stock, debt securities and/or warrants. The filing also includes a dedicated $100 million at-the-market (ATM) sales agreement with TD Securities (USA) LLC, giving management flexibility to raise capital "from time to time" as clinical milestones approach.
The prospectus reiterates Tectonic’s strategy of developing biologics that modulate GPCRs via its proprietary GEODe™ platform. Lead asset TX45 (Fc-relaxin fusion) has completed a Phase 1a study showing good tolerability and a favourable PK/PD profile. In Part A of an ongoing Phase 1b hemodynamic trial in PH-HFpEF patients, TX45 achieved a 19% reduction in pulmonary capillary wedge pressure and a >30% PVR reduction in a severe sub-population, with no serious adverse events. Recruitment is under way for Part B (PH-HFrEF), and the 24-week placebo-controlled Phase 2 APEX trial dosed its first patient in October 2024; topline data are expected in 2026.
Second program TX2100, a VHH-Fc fusion for Hereditary Hemorrhagic Telangiectasia, entered IND-enabling studies in Q2 2025, with a Phase 1 start targeted for late 2025/early 2026. The company completed a reverse-merger with Legacy Tectonic in June 2024 and now qualifies as a smaller reporting company. Proceeds from any sales under the shelf will fund pipeline advancement, working capital and potential in-licensing.
As of 3 July 2025 the stock traded at $21.34 per share. While the registration itself is not a financing event, it signals possible future dilution balanced by improved funding optionality ahead of multiple clinical catalysts.
FAQ
What is the current stock price of Rcm Tech (RCMT)?
What is the market cap of Rcm Tech (RCMT)?
What primary solutions does RCM Tech offer?
Which industries are served by RCM Tech?
How is RCM Tech structured in terms of business segments?
What sets RCM Tech apart from its competitors?
In which geographical markets does RCM Tech operate?
How does RCM Tech generate revenue?
What should investors know about RCM Tech's market approach?
